ArticleClinical epigenetics2026
Aging-driven transcriptional programs in diabetic kidney disease: multi-omics discovery of diagnostic biomarkers and drug-repurposing targets.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiabetic kidney disease (DKD) is the primary global cause of end-stage renal disease. However, the aging-related gene networks driving its progression remain unclear.
methodsIn this study, we integrated bioinformatics and experiments to screen for age-related hub genes in DKD and explore their diagnostic and therapeutic values. Transcriptomic datasets and aging-related gene databases were combined to obtain candidate differentially expressed genes enriched in the PI3K-Akt and JAK-STAT pathways. LASSO and Random Forest algorithms were applied to screen core hub genes, and a logistic diagnostic model was constructed for verification. Single-cell sequencing was utilized to clarify the main cell populations expressing key genes. Molecular docking and dynamics simulations were performed to analyze the binding stability of candidate drugs and target genes. High-glucose cell models and DKD rat models were established, and RT-qPCR, western blot, and pathological staining assays were used to validate the expression changes of key genes and the regulatory effects of drugs.
resultsNine hub genes (CLU, EGF, SLC16A7, MYC, RPA1, RB1, APOC3, SYK, and NR3C1) were finally screened out. The constructed logistic diagnostic model achieved an AUC of 0.881 in external verification. Glomerular endothelial cells and mesangial cells were identified as the main cell populations expressing these hub genes. Molecular simulation results confirmed the stable binding of fostamatinib to SYK and selexipag to APOC3. In vivo and in vitro validation experiments demonstrated that the two candidate agents could suppress NF-κB pathway activation, inflammatory cytokine release, and cellular senescence.
conclusionIn this study, we identified age-related hub genes, constructed a reliable diagnostic signature, and suggested SYK-fostamatinib and APOC3-selexipag as potential drug-repurposing candidates for DKD, which requires further experimental and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.